<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309500</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00178869</org_study_id>
    <nct_id>NCT04309500</nct_id>
  </id_info>
  <brief_title>SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting</brief_title>
  <acronym>SHARE(D)</acronym>
  <official_title>Development of Culturally-Sensitive and Patient-Centered Feedback for Alzheimer's Dementia Risk Disclosure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test efficacy and safety of person-centered, culturally-informed&#xD;
      protocols for disclosure of different combinations of Alzheimer's dementia risk factors.&#xD;
      Building on the results from a federally-funded assessment of preferences and needs of&#xD;
      racially diverse participants and their respective friends/family members, in regard to&#xD;
      Dementia - Alzheimer's Type, we have produced protocols for communication of DAT risk, with&#xD;
      attention to specific adaptations in style or content based on individual factors and&#xD;
      preferences. These protocols allow for communication of risk based on clinical history and&#xD;
      diagnosis, structural neuroimaging, apolipoprotein-E status, and amyloid and tau burden on&#xD;
      positron emission tomography. In particular, protocols specify (a) effective methods of&#xD;
      communicating risk conferred by each data source, (b) information designed for patients&#xD;
      versus informants, (c) psychoeducation needs, and (d) resource/support needs. We will recruit&#xD;
      a randomly-selected subset of 10 dyads (including 5 participants who are Non-Hispanic&#xD;
      African-American, 5 participants who are Non-Hispanic White) from the Stage I sample to whom&#xD;
      we will develop and implement personalized DAT risk disclosure protocols. We will provide&#xD;
      preliminary information on the effectiveness of these protocols in terms of&#xD;
      patient/co-participant comprehension and recall of feedback provided, and initial changes in&#xD;
      mood or behavior immediately following and shortly after risk disclosure sessions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, a divide exists between Dementia - Alzheimer's Type (DAT) risk information that is&#xD;
      shared in clinical settings versus genetic and biomarker-based risk information gathered and,&#xD;
      less frequently, disseminated in research settings. Clinical feedback continues to discuss&#xD;
      DAT risk in terms of personal/family history, neuropsychological or neurological testing, and&#xD;
      standard neuroimaging reports. Research advances in genotyping, quantitative neuroimaging,&#xD;
      and amyloid and tau positron emission tomography (PET) have improved our risk prediction and&#xD;
      disease staging; however, the literature on how to share these important findings is sparse.&#xD;
      Effective risk disclosure protocols are fundamentally dependent on the needs of recipients.&#xD;
      However, we do not know how patients, or those tasked with current or future caregiving,&#xD;
      decide what sources or types of risk information they want disclosed, nor their reasons for&#xD;
      preferring certain types of information over others. Given the differences between static&#xD;
      (e.g., family history, genotyping) and dynamic, potentially modifiable risk factors (e.g.,&#xD;
      amyloid burden), as well as varying familiarity with research-based biomarkers, it is&#xD;
      especially important to understand how much information patients hope to receive and what&#xD;
      they hope to do with it. This knowledge gap is particularly pertinent in minority and&#xD;
      low-income populations given systemic challenges and cultural beliefs that may affect their&#xD;
      psychological, physical, and financial ability to adapt to a high risk profile. Thus,&#xD;
      understanding risk disclosure needs and preferences is a critical step in developing&#xD;
      culturally-informed feedback protocols.&#xD;
&#xD;
      Aim 1 (accomplished during the Stage I observational Needs Assessment - HUM00160276) was to&#xD;
      investigate the preferences and needs of racially diverse participants, and their respective&#xD;
      informants, in regards to receiving feedback about their risk for DAT.&#xD;
&#xD;
      Aim 2 is to develop person-centered, culturally-informed protocols for disclosure of&#xD;
      different combinations of Alzheimer's dementia risk factors. Building on the results of Aim&#xD;
      1, we have produced protocols for communication of DAT risk, with attention to specific&#xD;
      adaptations in style or content based on individual factors and preferences. In particular,&#xD;
      protocols specify (a) effective methods of communicating risk conferred by each data source,&#xD;
      (b) information designed for patients versus informants, (c) psychoeducation needs, and (d)&#xD;
      resource/support needs. We will recruit a randomly-selected subset of 10 dyads (including 5&#xD;
      participants who are Non-Hispanic African-American, 5 participants who are Non-Hispanic&#xD;
      White) from the Stage I sample to whom we will develop and implement personalized DAT risk&#xD;
      disclosure protocols. We will provide preliminary information on the effectiveness of these&#xD;
      protocols in terms of patient/co-participant comprehension and recall of feedback provided,&#xD;
      and initial changes in mood or behavior immediately following and shortly after risk&#xD;
      disclosure sessions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Actual">January 31, 2022</completion_date>
  <primary_completion_date type="Actual">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Stage II will involve a clinical trial, with the risk disclosure feedback serving as the behavioral intervention. The study will use a single-group design with no control group. All 10 participant-co-participant dyads (5 Non-Hispanic African-American, 5 Non-Hispanic White) will receive feedback about the participant's DAT risk. Outcomes will be measured immediately following feedback and at 1- and 6-weeks following risk disclosure.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Personal Information Score (Immediate) - PARTICIPANT</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>This questionnaire asks participants a series of multiple choice and true/false questions about their understanding or memory of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Personal Information Score (Immediate) - CO-PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>This questionnaire asks co-participants a series of multiple choice and true/false questions about their understanding or memory of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Personal Information Score (1-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>This questionnaire asks participants a series of multiple choice and true/false questions about their understanding or memory of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Personal Information Score (1-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>This questionnaire asks co-participants a series of multiple choice and true/false questions about their understanding or memory of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Personal Information Score (6-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>This questionnaire asks participants a series of multiple choice and true/false questions about their understanding or memory of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Personal Information Score (6-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>This questionnaire asks co-participants a series of multiple choice and true/false questions about their understanding or memory of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Meaning of Risk Information Score (Immediate) - PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>This questionnaire asks participants a series of multiple choice and true/false questions about their understanding or memory of the meaning of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity (i.e., whether their profile on each of these indicators is related to increased, decreased, or unclear risk for DAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Meaning of Risk Information Score (Immediate) - CO-PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>This questionnaire asks co-participants a series of multiple choice and true/false questions about their understanding or memory of the meaning of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity (i.e., whether their profile on each of these indicators is related to increased, decreased, or unclear risk for DAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Meaning of Risk Information Score (1-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>This questionnaire asks participants a series of multiple choice and true/false questions about their understanding or memory of the meaning of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity (i.e., whether their profile on each of these indicators is related to increased, decreased, or unclear risk for DAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Meaning of Risk Information Score (1-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>This questionnaire asks co-participants a series of multiple choice and true/false questions about their understanding or memory of the meaning of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity (i.e., whether their profile on each of these indicators is related to increased, decreased, or unclear risk for DAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Meaning of Risk Information Score (6-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>This questionnaire asks participants a series of multiple choice and true/false questions about their understanding or memory of the meaning of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity (i.e., whether their profile on each of these indicators is related to increased, decreased, or unclear risk for DAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehension/Recall of Results - Meaning of Risk Information Score (6-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>This questionnaire asks co-participants a series of multiple choice and true/false questions about their understanding or memory of the meaning of the participant's current diagnosis, structural neuroimaging, APO-E genotype, and amyloid and/or tau positivity (i.e., whether their profile on each of these indicators is related to increased, decreased, or unclear risk for DAT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale - Short Form (GDS-15; Immediate) - PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>A 15-item assessment of depressive symptoms that has been adapted to remove common depression symptoms often conflated with normal aging (i.e., somatic symptoms). It asks the participant to rate the presence of mood symptoms over the past two weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale - Short Form (GDS-15; Immediate) - CO-PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>A 15-item assessment of depressive symptoms that has been adapted to remove common depression symptoms often conflated with normal aging (i.e., somatic symptoms). It asks the co-participant to rate the presence of mood symptoms over the past two weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale - Short Form (GDS-15; 1-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>A 15-item assessment of depressive symptoms that has been adapted to remove common depression symptoms often conflated with normal aging (i.e., somatic symptoms). It asks the participant to rate the presence of mood symptoms over the past two weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale - Short Form (GDS-15; 1-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>A 15-item assessment of depressive symptoms that has been adapted to remove common depression symptoms often conflated with normal aging (i.e., somatic symptoms). It asks the co-participant to rate the presence of mood symptoms over the past two weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale - Short Form (GDS-15; 6-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>A 15-item assessment of depressive symptoms that has been adapted to remove common depression symptoms often conflated with normal aging (i.e., somatic symptoms). It asks the participant to rate the presence of mood symptoms over the past two weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scale - Short Form (GDS-15; 6-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>A 15-item assessment of depressive symptoms that has been adapted to remove common depression symptoms often conflated with normal aging (i.e., somatic symptoms). It asks the co-participant to rate the presence of mood symptoms over the past two weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Anxiety Inventory (BAI; Immediate) - PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>A 21-item measure of the perceived severity ('not at all' to 'severely') at which the participant is experiencing anxiety symptoms over the past week, validated for use with older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Anxiety Inventory (BAI; Immediate) - CO-PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>A 21-item measure of the perceived severity ('not at all' to 'severely') at which the co-participant is experiencing anxiety symptoms over the past week, validated for use with older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Anxiety Inventory (BAI; 1-week follow-up) - PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>A 21-item measure of the perceived severity ('not at all' to 'severely') at which the participant is experiencing anxiety symptoms over the past week, validated for use with older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Anxiety Inventory (BAI; 1-week follow-up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>A 21-item measure of the perceived severity ('not at all' to 'severely') at which the co-participant is experiencing anxiety symptoms over the past week, validated for use with older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Anxiety Inventory (BAI; 6-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>A 21-item measure of the perceived severity ('not at all' to 'severely') at which the participant is experiencing anxiety symptoms over the past week, validated for use with older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beck Anxiety Inventory (BAI; 6-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>A 21-item measure of the perceived severity ('not at all' to 'severely') at which the co-participant is experiencing anxiety symptoms over the past week, validated for use with older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Impact of Genetic Testing for AD (IGT-AD; Immediate) - PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>The Impact of Genetic Testing for AD (IGT-AD) is a 16-item self-report measure that assesses two positive and negative emotional responses to genetic AD risk disclosure. We will adapt this scale to more broadly assess the 'life event' of receiving DAT risk disclosure based on multiple indicators. Participants will complete this to assess their reactions to the participant receiving risk feedback.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Impact of Genetic Testing for AD (IGT-AD; Immediate) - CO-PARTICIPANTS</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>The Impact of Genetic Testing for AD (IGT-AD) is a 16-item self-report measure that assesses two positive and negative emotional responses to genetic AD risk disclosure. We will adapt this scale to more broadly assess the 'life event' of receiving DAT risk disclosure based on multiple indicators. Co-participants will complete this to assess their reactions to the participant receiving risk feedback.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Impact of Genetic Testing for AD (IGT-AD; 1-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 1 week after risk disclosure</time_frame>
    <description>The Impact of Genetic Testing for AD (IGT-AD) is a 16-item self-report measure that assesses two positive and negative emotional responses to genetic AD risk disclosure. We will adapt this scale to more broadly assess the 'life event' of receiving DAT risk disclosure based on multiple indicators. Participants will complete this to assess their reactions to the participant receiving risk feedback.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Impact of Genetic Testing for AD (IGT-AD; 1-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 1 week after risk disclosure</time_frame>
    <description>The Impact of Genetic Testing for AD (IGT-AD) is a 16-item self-report measure that assesses two positive and negative emotional responses to genetic AD risk disclosure. We will adapt this scale to more broadly assess the 'life event' of receiving DAT risk disclosure based on multiple indicators. Co-participants will complete this to assess their reactions to the participant receiving risk feedback.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Impact of Genetic Testing for AD (IGT-AD; 6-week Follow-Up) - PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks after risk disclosure</time_frame>
    <description>The Impact of Genetic Testing for AD (IGT-AD) is a 16-item self-report measure that assesses two positive and negative emotional responses to genetic AD risk disclosure. We will adapt this scale to more broadly assess the 'life event' of receiving DAT risk disclosure based on multiple indicators. Participants will complete this to assess their reactions to the participant receiving risk feedback.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Impact of Genetic Testing for AD (IGT-AD; 6-week Follow-Up) - CO-PARTICIPANTS</measure>
    <time_frame>Administered at 6 weeks after risk disclosure</time_frame>
    <description>The Impact of Genetic Testing for AD (IGT-AD) is a 16-item self-report measure that assesses two positive and negative emotional responses to genetic AD risk disclosure. We will adapt this scale to more broadly assess the 'life event' of receiving DAT risk disclosure based on multiple indicators. Co-participants will complete this to assess their reactions to the participant receiving risk feedback.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Comprehension of Results - Qualitative Impressions</measure>
    <time_frame>Administered immediately after risk disclosure</time_frame>
    <description>Participants and co-participants will be asked to explain, in their own words and without cuing, their impressions of the messages they received about the participant's clinical history, structural neuroimaging, genetic profile, and amyloid and tau biomarkers, as well as the risk for DAT conferred by those markers. Responses will be transcribed and coded to determine core themes and understanding of risk messages.</description>
  </other_outcome>
  <other_outcome>
    <measure>Recall of Results - Qualitative Impressions (1-week Follow-Up)</measure>
    <time_frame>Administered at 1 week post risk disclosure</time_frame>
    <description>Participants and co-participants will be asked to explain, in their own words and without cuing, their impressions of the messages they received about the participant's clinical history, structural neuroimaging, genetic profile, and amyloid and tau biomarkers, as well as the risk for DAT conferred by those markers. Responses will be transcribed and coded to determine core themes and understanding of risk messages.</description>
  </other_outcome>
  <other_outcome>
    <measure>Recall of Results - Qualitative Impressions (6-week Follow-Up)</measure>
    <time_frame>Administered at 6 weeks post risk disclosure</time_frame>
    <description>Participants and co-participants will be asked to explain, in their own words and without cuing, their impressions of the messages they received about the participant's clinical history, structural neuroimaging, genetic profile, and amyloid and tau biomarkers, as well as the risk for DAT conferred by those markers. Responses will be transcribed and coded to determine core themes and understanding of risk messages.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Healthy Aging</condition>
  <arm_group>
    <arm_group_label>African-American Participant-Co-Participant Dyads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Non-Hispanic African-American participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>White Participant-Co-Participant Dyads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Non-Hispanic White participants and their respective caregivers will receive semi-structured personalized feedback regarding their risk for Dementia-Alzheimer's type (DAT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Personalized DAT Risk Disclosure Protocol</intervention_name>
    <description>Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.</description>
    <arm_group_label>African-American Participant-Co-Participant Dyads</arm_group_label>
    <arm_group_label>White Participant-Co-Participant Dyads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 65+ years&#xD;
&#xD;
          -  Non-Hispanic Black or Non-Hispanic White race/ethnicity&#xD;
&#xD;
          -  Previously participated in Stage I (observational needs assessment)&#xD;
&#xD;
          -  Have completed an initial evaluation as part of the University of Michigan Memory and&#xD;
             Aging Project (UM-MAP), Stimulation to Improve Memory (STIM) study, or the DAPPER&#xD;
             study within the last 12 months.&#xD;
&#xD;
          -  Diagnosed with normal cognition or mild cognitive impairment (MCI; single- or&#xD;
             -multiple domain, amnestic or non-amnestic forms)&#xD;
&#xD;
          -  Able to identify a co-participant who is currently the participant's caregiver, or&#xD;
             would serve in this role in the future if needed, and well-known to the participant&#xD;
             (known for â‰¥5 years and have at least weekly phone or in-person contact)&#xD;
&#xD;
          -  Able to identify a co-participant who is 18+ years old.&#xD;
&#xD;
          -  Able to identify a co-participant who is cognitively healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or historical neurologic disorder (e.g., Alzheimer's dementia or other&#xD;
             neurodegenerative dementia, Parkinson's disease, seizure disorder, tumor, multiple&#xD;
             sclerosis)&#xD;
&#xD;
          -  Current or historical significant neurologic injury (e.g., significant stroke or&#xD;
             moderate-severe head injury, defined by loss of consciousness &gt; 5 minutes, presence of&#xD;
             significant post-traumatic amnesia, or the need for extended hospitalization or&#xD;
             intervention).&#xD;
&#xD;
          -  Motor symptoms indicative of a neurodegenerative etiology other than Alzheimer's&#xD;
             disease&#xD;
&#xD;
          -  Severe mental illness (i.e., bipolar disorder, thought disorder, psychosis)&#xD;
&#xD;
          -  Severe substance use disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Michigan Medical School, Department of Psychiatry</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>September 29, 2022</last_update_submitted>
  <last_update_submitted_qc>September 29, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Annalise Rahman-Filipiak</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be made available to other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 26, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04309500/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Consent Form - Co-Participants</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 26, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04309500/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Consent Form - Co-Participants</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 26, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04309500/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

